Ascendis Pharma A/S (ASND) 株式分析

企業概要

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to developing and commercializing TransCon-based therapies designed to address significant unmet medical needs within the healthcare sector across Europe, the United States, and international markets. The company operates specifically within the biotechnology industry, focusing on the creation of therapeutic solutions such as SKYTROFA for treating growth hormone deficiency in pediatric patients and YORVIPATH for oncology applications. According to current market data, Ascendis Pharma A/S maintains a market capitalization of $14.84B and reports annual revenue (TTM) of $720.13M, employing a workforce of 1,189 individuals. These valuation and revenue figures indicate that the company has established itself as a substantial entity within the biotechnology landscape, possessing a market presence that commands significant investor attention despite being in a capital-intensive development phase.

財務健全性

The financial performance of Ascendis Pharma A/S over the trailing twelve months (TTM) reflects a revenue stream of $720.13M, contrasted against a net income of -$228.034M and an EBITDA of -$131.415M. The substantial gap between positive revenue and significant negative net income reveals a cost structure characterized by high operational expenses, which is typical for biotechnology firms in the research and commercialization phases where R&D and manufacturing costs often exceed immediate earnings. Despite the reported net loss, the company demonstrates notable financial flexibility through a positive free cash flow of $164.71M, suggesting that cash generation from operations exceeds capital expenditures. This positive free cash flow is a critical indicator of the company's ability to fund future development programs without relying solely on external financing. The margin profile presents a complex picture: a gross margin of 86.8% highlights the high value of the therapeutic products, while an operating margin of 1.0% and a profit margin of -31.7% indicate that overhead costs are currently consuming the majority of gross profits. On the balance sheet, the company holds cash of $616.04M against total debt of $871.79M, while the debt-to-equity ratio is listed as N/A due to the absence of positive equity in the standard calculation. The current ratio stands at 1.04, indicating that the company possesses slightly more current assets than current liabilities, though the margin is relatively tight for a cash-intensive industry. Return on Equity (ROE) is N/A, reflecting the negative equity position common in pre-profitability biotech firms, while Return on Assets (ROA) stands at -6.9%, signaling that total assets are currently generating negative returns.

バリュエーション評価

Valuation metrics for Ascendis Pharma A/S highlight the market's expectations for future profitability rather than current earnings power, as evidenced by a trailing P/E ratio (TTM) of N/A and a forward P/E of 19.59. The absence of a trailing P/E and the presence of a forward P/E imply that investors are pricing the stock based on anticipated future earnings recovery rather than current profitability, suggesting an expectation of an upward earnings trajectory. The price-to-book ratio is -78.72, a negative figure that typically indicates the market value is detached from the net asset value, a common characteristic for biotechnology companies with significant intangible assets and negative book equity. Alternative valuation metrics such as a price-to-sales ratio of 20.61 and an EV/EBITDA of -114.84 further suggest that the market is valuing the company based on its sales growth potential and pipeline value rather than current cash flow or earnings. The stock price has traded within a range defined by a 52-week high of $248.60 and a 52-week low of $124.06, providing context for the current market sentiment. The beta value of 0.48 indicates that the stock exhibits lower volatility relative to the broader market, moving less than half as much as the market index during periods of fluctuation.

Growth & Income

Ascendis Pharma A/S is currently experiencing a revenue growth rate of 42.3% year-over-year, while earnings growth is N/A due to the company's ongoing net losses. The disparity between robust revenue expansion and the absence of earnings growth implies that the company is prioritizing market share acquisition and product development over immediate profitability, a strategy consistent with the biotechnology sector's lifecycle. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available earnings and cash flows are being retained and reinvested into growth initiatives rather than distributed to shareholders. This reinvestment strategy is essential for funding the development of its TransCon-based therapies and securing regulatory approvals for SKYTROFA and YORVIPATH. The overall growth and income profile for Ascendis Pharma A/S is characterized by strong top-line expansion supported by positive free cash flow, yet it remains dependent on future profitability to achieve a positive return on equity.